Dante Pieramici MD

Retinal Disease

Director California Retina Research Foundation

525 E Micheltorena StSte ASanta Barbara, CA 93103
Phone+1 805-963-1648
Fax+1 661-322-8489

Dr. Pieramici is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pieramici's full profile Already have an account?

Summary

Dr. Dante Pieramici is an ophthalmologist in Santa Barbara, CA and is affiliated with multiple hospitals in the area, including Community Memorial Hospital, Goleta Valley Cottage Hospital, Providence Saint John's Health Center, and Santa Barbara Cottage Hospital. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 26 years. He specializes in retinal disease and is experienced in retina surgery, general / comprehensive ophthalmology, vitreoretinal disease, and pediatric retinal disease.

Education & Training

Johns Hopkins UniversityResidency, Ophthalmology, 1992 - 1995
University of Chicago (NorthShore)Internship, Transitional Year, 1991 - 1992
Johns Hopkins University School of MedicineClass of 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2001 - 2026
MD State Medical License 1996 - 2005
CT State Medical License 1997 - 1998
GA State Medical License 1995 - 1997
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification IntelleChart, MDIntelleSys, A Nextech Company, 2017
Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012

Clinical Trials

Lucentis for Central Retinal Vein Occlusion (CRVO) Start of enrollment: 2006 Jan 01
Completed
Phase 1
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT) Start of enrollment: 2006 May 01
Completed
Phase 2
Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion Start of enrollment: 2010 Jan 01
Completed
Phase 1

Publications & Presentations

PubMed

MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.
Avery W Zhou, Ryan A Sahraravand, Liisa M Baumann, Gail Megan Teagle, Jeremiah Brown
Ophthalmologica. Journal International D'ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde. 2026-01-01
1 citations
Refillable Drug Reservoirs for Retinal Vascular Diseases.
Andrew J Clark, Carl Regillo, Shamika Gune, Dante J Pieramici
American Journal of Ophthalmology. 2025-09-01
Reply to Comment on Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular...
David A Eichenbaum, Nancy Holekamp, Arshad M Khanani, Dante Pieramici, Vrinda Hershberger
American Journal of Ophthalmology. 2025-08-01

Authored Content

The Port Delivery System with RanibizumabMarch 2019

Press Mentions

Ranibizumab Ocular Implant Shows Long-Term Benefits in Retinal DiseaseJune 5th, 2025
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study to Evaluate Ixo-Vec for Wet AMDMarch 3rd, 2025
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD StudyJanuary 15th, 2025